课题基金 / 基金详情

MANIPULATION OF IMMUNE PROCESSES WITH HETEROCROSSLINKED ANTIBODIES

MANIPULATION OF IMMUNE PROCESSES WITH HETEROCROSSLINKED ANTIBODIES
用异源交联抗体操纵免疫过程
批准号:
3916401
负责人:
D M SEGAL
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:

项目摘要

项目成果

D M SEGAL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
1. Targeted T cell cytotoxicity resides in the low density fraction of PBL. Activity can be generated in the high density fraction by treatment with antiCD3 antibody and IL-2. 2. Targeted tumoristatic activity has been detected in a long term in vitro tumor growth assay. This activity resides in the T4+ and T8+ subsets of T cells. 3. Human T cells and K cells targeted with anti-T3 and anti-FcR, heterocrosslinked to anti-tumor antibodies eradicate established human ovarian cancer cells in nude mice. 4. Heterocrosslinked antibodies containing an antibody against a soluble antigen linked to an antibody against a cell surface determinant on an antigen presenting cell (APC), greatly enhance the efficiency of antigen presentation. Enhanced presentation has been seen when antigen was targeted to Fc receptors, surface immunoglobulin, MHC class I and MHC class II molecules on the APC. Targeted antigen presentation is antigen specific and I-A restricted.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TARGETED CELLULAR CYTOTOXICITY
ACTIVATION AND TRIGGERING OF CYTOXIC CELLS
ACTIVATION AND TRIGGERING OF CYTOXIC CELLS
TARGETED CELLULAR CYTOTOXICITY
海外基金